Roche (RHHBY.US) breast cancer drug Wilserdly wins FDA approval: analysts forecast peak annual sales of up to US$14.5 billion
Roche's (RHHBY.US) new oral breast cancer drug has received approval from U.S. regulators, clearing the way for a medicine the pharmaceutical company hopes will change the way the disease is treated.
Roche Holding (RHHBY.US)'s new oral breast cancer drug has won approval from U.S. regulators, clearing the way for a medicine the company hopes will change the way the disease is treated.
The U.S. Food and Drug Administration (FDA) said Monday it approved the regimen, called Wilserdly, for use in combination with a targeted cancer therapy to treat locally advanced or metastatic breast cancer driven by a certain gene mutation, in patients whose cancer has recurred or progressed after prior treatment.
The drug is taken once daily until the disease worsens or the patient develops unacceptable toxic side effects. The approval carries warning labels for the risk of bradycardia (dangerously slow heart rate) and fetal toxicity in pregnant women.
Roche's move is aimed at capturing a emerging class of drugs that could reshape the treatment landscape for the most common form of breast cancer. The success or failure of Wilserdly is critical for the Swiss drugmakeranalysts forecast the drug will become a blockbuster with peak annual sales of between US$2.5 billion and US$14.5 billion.
Following the approval news, Roche Holding's American Depositary Receipts (ADR) rose 1.2% at 3:32 p.m. New York time.
The FDA said the approval was based on the drug's ability to delay median cancer progression by 4.5 months compared with an older combination regimen. However, regulators also noted it is too early to determine whether the drug can extend patients' overall survival.
A Roche spokesperson did not immediately respond to questions about pricing.
Related Articles

HUAJIN INTL (02738): Subsidiary Huajin Metal Products Issued Consumption Restriction Order; Huamu Hardware Listed as Person Subject to Enforcement

HK Bull/Bear Outstanding Qty Ratio(52:48) | November 17

Agora, Inc. Sponsored ADR Class A (API.US) Q3 revenue up 19% year-over-year, profitable for the eighth consecutive quarter.
HUAJIN INTL (02738): Subsidiary Huajin Metal Products Issued Consumption Restriction Order; Huamu Hardware Listed as Person Subject to Enforcement

HK Bull/Bear Outstanding Qty Ratio(52:48) | November 17

Agora, Inc. Sponsored ADR Class A (API.US) Q3 revenue up 19% year-over-year, profitable for the eighth consecutive quarter.






